Core Insights - The "2025 Global Women's Forum" held in Beijing focuses on the theme "Resilience Power, Creating the Future," aiming to establish a comprehensive platform for women's brand experiences in China [2][5] - The forum features three main themes, four sub-forums, and over twenty influential speakers discussing women's resilience in the context of global changes, technological innovations, and social transformations [2][5] Group 1: Key Themes and Discussions - The core topic of the forum is how women can leverage resilience to face challenges and create future opportunities amidst significant global changes [5] - Yang Lan emphasizes that resilience is crucial for coping with uncertainties, highlighting women's unique traits such as empathy and communication skills, which are increasingly valuable in the AI era [7][11] - The "Wutong Growth Model" introduced by the "Global Women's Research Institute" integrates theories of women's development and lifelong learning, providing a comprehensive growth path for women [7][11] Group 2: Notable Speakers and Their Contributions - Yang Liu shares stories of outstanding women in the culinary industry, illustrating how their resilience has allowed them to become key players in their fields [9] - Gabrielle Saint-Genis discusses the importance of resilience in business, sharing key principles for navigating change and maintaining brand value [11] - Wang Shi highlights the impact of women's strength and resilience in achieving significant challenges, asserting that women's influence extends beyond just half of society [13] Group 3: Economic and Innovation Insights - Guan Qingyou analyzes the economic transformation and business opportunities in the context of global supply chain rebalancing, stressing the need for resilience in the current economic environment [17] - Wang Shutong discusses the opportunities for female entrepreneurs in the evolving landscape of globalization and community-based economies [15] - Han Ying emphasizes the unique value women bring to their careers, linking resilience to the ability to innovate and adapt in their fields [19] Group 4: Psychological Resilience and Personal Growth - Various speakers, including Wei Wei and Ni Xiaolian, share personal stories of overcoming challenges, emphasizing the importance of psychological resilience in personal and professional growth [25][27] - Zhang Xichao discusses the significance of self-awareness in developing resilience and happiness, highlighting its role in navigating life's challenges [31] - Liu Genghong and Wang Wanfei illustrate how maintaining personal rhythm and passion contributes to psychological resilience [33] Group 5: Awards and Recognition - The "2025 Women's Creativity Awards" ceremony honors female leaders who have demonstrated exceptional creativity in their respective fields, showcasing the achievements of women across various industries [37]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 於股東週年大會日期，已發行股份總數為1,067,446,849股股份，即賦予本公司股東（「股東」） 權利出席股東週年大會並於會上就提呈決議案投票的股份總數。概無股份賦予股東權利出席 股東週年大會，惟須根據上市規則第13.40條於股東週年大會上放棄投票贊成提呈決議案，亦 無股東須根據上市規則於股東週年大會上就所提呈之決議案放棄投票。概無任何人士於股東 週年大會通函內表明其有意於股東週年大會上投票就任何提呈之決議案投反對票或放棄投 票。 Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 於2025年8月29日（星期五）舉行之 股東週年大會投票表決結果 董事會欣然宣佈，股東週年大會通告所載的全部提呈決議案已於2025年8月29日（星期五） 舉行之股東週年大會上以股東投票表決方式獲正式通過。 茲提述醫渡科技有限公司（「本公司」） ...

来源：智通财经网 2025年8月26日，港股上市公司投资日志如下： 类别公司 新股活动 奥克斯电气 (招股中) 双登股份 (上市日) （除净日） 九龙仓置业 大方广瑞德 子不语 派格生物医药-B 新矿资源 飞扬集团 中广核矿业 裕程物流 利基控股 涂鸦智能-W 中油燃气 泰达生物 汉国置业 民富国际 优越集团控股 医渡科技 创业集团控股 扬科集团 中国神华 友联国际教育租赁 建业实业 业绩公布日 股东大会召开日 分红派息 港灯-SS （除净日） 阳光房地产基金 （除净日） 锅圈 （除净日） 珩湾科技 （派息日） 环联连讯 （除净日） 六福集团 （除净日） 富士高实业 （除净日） 华信地产财务 （除净日） 弥明生活百货 （除净日） 结好控股 （除净日） 米高集团 （除净日） 安全货仓 （除净日） （除净日） 大洋环球控股 （派息日） 大唐环境 （派息日） 大唐新能源 （派息日） 江西银行 （除净日） 力宝 （除净日） 中国动向 （除净日） 东方企控集团 宜宾银行 （派息日） 长安民生物流 （派息日） 易大宗 （除净日） 复锐医疗科技 （除净日） ...

Core Insights - Medical technology company Yidu Tech (02158) saw its stock rise over 5%, currently trading at 6.65 HKD with a transaction volume of 69.47 million HKD [1] Group 1: Product Development and Innovations - Yidu Tech, in collaboration with Guangdong Medical University Affiliated Hospital, launched the "Multimodal Disease Database for Vascular Diseases" and "Meiyi Intelligent Body" at the 2025 Academic Annual Meeting of the Guangdong Provincial Hospital Association [1] - The "Meiyi Intelligent Body" serves as a core technology platform, marking Yidu Tech's first application of its large model in the medical aesthetics field [1] Group 2: Digital Health Initiatives - At the 2025 Digital Therapy Conference, Yidu Tech presented its achievements in the "2+3" diabetes management project in Hainan, highlighting its role as an AI medical enterprise [1] - Since the pilot program began in 2023, Yidu Tech has collaborated closely with Ling Shui County, achieving a 99.09% inclusion rate of managed patients into systematic care, with fasting blood glucose and glycated hemoglobin compliance rates improving by 18.63% and 4.68%, respectively, surpassing the provincial average [1] - Following Ling Shui, the company plans to extend its AI medical innovations to cities such as Sanya, Wanning, Qionghai, and Wenchang, with an aim to expand digital therapy services for hypertension and other chronic diseases, targeting coverage for over 100,000 regional patients by 2025 [1]

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.65 HKD, with a transaction volume of 69.47 million HKD, following the announcement of its collaboration with Guangdong Medical University Affiliated Hospital on a specialized database for vascular diseases and the "Meiyi Intelligent Body" [1] Group 1: Product Development and Innovation - The "Meiyi Intelligent Body," developed in collaboration with Guangdong Medical University, represents Yidu Technology's first application of its large model in the medical aesthetics field [1] - The company showcased its technological advancements at the 2025 Academic Annual Meeting of the Guangdong Provincial Hospital Association's Plastic Surgery Professional Committee [1] Group 2: Digital Health Initiatives - At the 2025 Digital Therapy Conference, Yidu Technology reported its involvement in the "2+3" diabetes management project in Hainan, highlighting its achievements since the pilot program began in 2023 [1] - The collaboration with Ling Shui County has resulted in 99.09% of managed patients being integrated into a systematic care program, with significant improvements in fasting blood glucose and glycated hemoglobin levels, increasing by 18.63% and 4.68% respectively, surpassing the provincial average [1] - The company plans to expand its AI healthcare innovations to other cities such as Sanya, Wanning, Qionghai, and Wenchang, and aims to extend digital therapy services to more chronic diseases like hypertension, targeting coverage for over 100,000 regional patients by 2025 [1]

Core Insights - Medical technology company Yidu Tech (02158) saw its stock rise over 5%, currently trading at 6.65 HKD with a transaction volume of 69.47 million HKD [1] Group 1: Product Development and Innovations - Yidu Tech, in collaboration with Guangdong Medical University Affiliated Hospital, launched the "Multimodal Specialty Database for Vascular Diseases" and "Meiyi Intelligent Body" at the 2025 Academic Annual Meeting of the Guangdong Provincial Hospital Association [1] - The "Meiyi Intelligent Body" serves as a core technology platform developed by Yidu Tech and the hospital's plastic surgery department, marking the company's first application of its large model in the medical aesthetics field [1] Group 2: Digital Health Initiatives - At the 2025 Digital Therapy Conference, Yidu Tech presented its achievements in the "2+3" diabetes management project in Hainan, highlighting its role as an AI healthcare enterprise [1] - Since the pilot program began in 2023, Yidu Tech has closely collaborated with Ling Shui County to address issues in doctor-patient communication, achieving a 99.09% inclusion rate of managed patients into systematic care [1] - The fasting blood glucose and glycated hemoglobin compliance rates improved by 18.63% and 4.68% from baseline levels, significantly exceeding the provincial average [1] - Following Ling Shui, the company plans to extend its AI healthcare innovations to cities such as Sanya, Wanning, Qionghai, and Wenchang, with plans to expand digital therapy services for hypertension and other chronic diseases, aiming to cover over 100,000 regional patients by 2025 [1]

Core Viewpoint - The integration of data is essential for the collaborative development of the "Three Medicines" (medical care, medical insurance, and pharmaceuticals), and enhancing data quality and standards is crucial for effective data utilization in this sector [1][2][3]. Group 1: Data Quality and Standards - Experts emphasize that data is a key element in promoting the collaborative development of the "Three Medicines" [1]. - There is a need to strengthen data quality and establish comprehensive data standards for the "Three Medicines" to facilitate efficient data circulation and utilization [1][2]. - The China Information Communication Research Institute is actively involved in developing technical standards and policies to enhance data classification and privacy protection [1][2]. Group 2: Medical Insurance Data - The quality of medical insurance data is currently the best among the "Three Medicines," with initiatives like the National Smart Medical Insurance Competition promoting cross-regional data integration [2]. - Future efforts should focus on improving the data circulation system and regulatory mechanisms to enhance data quality from the source [2]. - The National Medical Insurance Bureau has mandated that by July 1, 2025, all tertiary hospitals must implement code-based settlements, which will significantly enhance data connectivity across the pharmaceutical supply chain [3]. Group 3: Digital Transformation in Traditional Medicine - The integration of digital technology into traditional Chinese medicine is being prioritized, with policies aimed at promoting "smart traditional Chinese medicine" [4]. - Companies are developing comprehensive models that combine medical technology, data, services, and research to enhance the digital capabilities of traditional medicine [4]. Group 4: Standardization Challenges - The lack of standardized medical data across various departments and regions is a significant challenge for the "Three Medicines" collaboration [5]. - There is a call for the establishment of a national medical terminology system and the promotion of international standards like ICD-11 and SNOMED CT in China [5]. - The focus should be on creating a supportive framework for data conversion while respecting the unique standards of each sector within the "Three Medicines" [5][6]. Group 5: Future Directions - The health sector is recognized as an early adopter of market-oriented data elements, with a commitment to advancing data sharing as a top priority [6]. - The "新华数字经济沙龙" series aims to foster high-level exchanges and discussions on digital economic development, focusing on innovative practices and addressing key issues in the digital economy [6].

Core Insights - The Chinese government has approved a policy to further implement the "Artificial Intelligence +" initiative, emphasizing strong support for AI applications in various sectors, particularly healthcare [1] - Securities firms believe that AI applications in healthcare, such as AI pathology diagnosis, AI imaging, and AI pharmaceuticals, are maturing and may accelerate commercialization [1] - Companies in the healthcare sector are launching AI models, with notable examples including YiduCore by Yidu Technology, a clinical thinking model by Weining Health, and "Xihe No. 1" by Beijing Boya [1] Group 1: AI in Healthcare - AI is expected to become a strategic engine for a new wave of technological revolution and industrial transformation, with a focus on AI healthcare applications [1] - The "Xihe No. 1" model differentiates itself by using rigorous clinical data from hospital case files, replacing less reliable internet data [2] - The model has been developed over nearly 10 years, utilizing data from 18 medical institutions and 1 million real case studies, achieving a coverage rate of 98% and a precision rate of over 90% in medical knowledge [2] Group 2: Addressing Healthcare Challenges - The "Xihe No. 1" model aims to address high misdiagnosis rates (over 25%) and delays in treatment, which can increase mortality risk by 35% [3] - A strategic partnership has been established to enhance AI-driven health management in Ningxia, focusing on improving access to healthcare in remote areas [3] - The company aims to bridge the gap in medical resources, allowing patients to receive expert-level guidance through AI [3] Group 3: Future Directions - The company plans to expand its AI healthcare services, targeting over 100 million patient interactions within three years [4] - Future developments will include AI smart terminal hardware products such as smart wheelchairs and nutritional management devices [4] - The establishment of a global medical AI collaboration network is intended to enhance model accuracy and facilitate global sharing of medical wisdom [4]

Core Viewpoint - Yidu Technology (02158) saw a significant increase in stock price, rising over 5% to HKD 6.43, with a trading volume of HKD 36.58 million, following its presentation at the T20+ Conference focused on innovation in new drug development [1] Group 1: Company Developments - Yidu Technology showcased its integrated AI-driven clinical research solution at the T20+ Conference, emphasizing its role in enhancing clinical research efficiency [1] - The company has served over 350 domestic and international pharmaceutical enterprises, accumulating experience from 686 clinical trial projects and conducting 275 real-world research projects [1] - The Vice President of Life Sciences Clinical Trials at Yidu Technology highlighted the advantages of their proprietary "AI Medical Brain" YiduCore, which optimizes the entire clinical trial process [1] Group 2: Industry Impact - The integrated solution presented by Yidu Technology significantly accelerates key drug development processes, improving efficiency by over 30% in areas such as trial design, patient recruitment, and clinical operations [1] - The advancements in AI-driven solutions are positioned to enhance research efficiency, optimize product launch pathways, and reduce innovation costs within the pharmaceutical industry [1]

Core Viewpoint - Yidu Technology (02158) experienced a significant stock increase of over 5%, closing at 6.43 HKD with a trading volume of 36.58 million HKD, following its participation in the T20+ Conference focused on innovation in new drug development [1] Group 1: Company Developments - Yidu Technology showcased its integrated AI-driven clinical research solution at the T20+ Conference, emphasizing its role in enhancing clinical research efficiency [1] - The company has served over 350 domestic and international pharmaceutical enterprises, accumulating experience from 686 clinical trial projects and conducting 275 prospective and retrospective real-world research projects [1] - Yidu Technology's Vice President of Life Sciences Clinical Trials, Liu Ying, highlighted the advantages of the company's medical big data processing capabilities and the proprietary "AI Medical Brain" YiduCore, which supports the entire clinical trial process [1] Group 2: Industry Insights - The T20+ Conference, guided by the China Food and Drug Enterprise Quality Safety Promotion Association, focused on key issues related to industrial upgrading and innovation in the entire chain of new drug research and development [1] - The integrated solution presented by Yidu Technology significantly accelerates critical drug development processes, improving efficiency by over 30% in areas such as clinical trial protocol optimization, patient recruitment, and clinical operations [1]